366 related articles for article (PubMed ID: 32712319)
1. Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein/kinin and the renin-angiotensin systems.
Fang C; Schmaier AH
Pharmacol Res; 2020 Oct; 160():105096. PubMed ID: 32712319
[TBL] [Abstract][Full Text] [Related]
2. Physiologic activities of the contact activation system.
Schmaier AH
Thromb Res; 2014 May; 133 Suppl 1(0 1):S41-4. PubMed ID: 24759141
[TBL] [Abstract][Full Text] [Related]
3. A Novel Antithrombotic Mechanism Mediated by the Receptors of the Kallikrein/Kinin and Renin-Angiotensin Systems.
Schmaier AH
Front Med (Lausanne); 2016; 3():61. PubMed ID: 27965959
[TBL] [Abstract][Full Text] [Related]
4. Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?
Meini S; Zanichelli A; Sbrojavacca R; Iuri F; Roberts AT; Suffritti C; Tascini C
Front Immunol; 2020; 11():2014. PubMed ID: 32849666
[TBL] [Abstract][Full Text] [Related]
5. The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities.
Schmaier AH
J Thromb Haemost; 2016 Jan; 14(1):28-39. PubMed ID: 26565070
[TBL] [Abstract][Full Text] [Related]
6. Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor.
Stavrou EX; Fang C; Merkulova A; Alhalabi O; Grobe N; Antoniak S; Mackman N; Schmaier AH
Blood; 2015 Jan; 125(4):710-9. PubMed ID: 25339356
[TBL] [Abstract][Full Text] [Related]
7. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin.
Shariat-Madar Z; Mahdi F; Warnock M; Homeister JW; Srikanth S; Krijanovski Y; Murphey LJ; Jaffa AA; Schmaier AH
Blood; 2006 Jul; 108(1):192-9. PubMed ID: 16514058
[TBL] [Abstract][Full Text] [Related]
8. Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system.
Schmaier AH
Int Immunopharmacol; 2008 Feb; 8(2):161-5. PubMed ID: 18182220
[TBL] [Abstract][Full Text] [Related]
9. G Protein-Coupled Kinin Receptors and Immunity Against Pathogens.
Scharfstein J; Ramos PIP; Barral-Netto M
Adv Immunol; 2017; 136():29-84. PubMed ID: 28950949
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of cardiac function and activation of anti-inflammatory vasoactive peptides expression in the rat myocardium by low level laser therapy.
Manchini MT; Serra AJ; Feliciano Rdos S; Santana ET; Antônio EL; de Tarso Camillo de Carvalho P; Montemor J; Crajoinas RO; Girardi AC; Tucci PJ; Silva JA
PLoS One; 2014; 9(7):e101270. PubMed ID: 24991808
[TBL] [Abstract][Full Text] [Related]
11. A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.
Steen Burrell KA; Layzer J; Sullenger BA
J Thromb Haemost; 2017 Sep; 15(9):1807-1817. PubMed ID: 28632925
[TBL] [Abstract][Full Text] [Related]
12. Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions.
Schmaier AH
Curr Opin Hematol; 2000 Sep; 7(5):261-5. PubMed ID: 10961574
[TBL] [Abstract][Full Text] [Related]
13. The arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimers.
Wilson PC; Lee MH; Appleton KM; El-Shewy HM; Morinelli TA; Peterson YK; Luttrell LM; Jaffa AA
J Biol Chem; 2013 Jun; 288(26):18872-84. PubMed ID: 23661707
[TBL] [Abstract][Full Text] [Related]
14. Assembly and activation of the plasma kallikrein/kinin system: a new interpretation.
Shariat-Madar Z; Mahdi F; Schmaier AH
Int Immunopharmacol; 2002 Dec; 2(13-14):1841-9. PubMed ID: 12489798
[TBL] [Abstract][Full Text] [Related]
15. Different cross-talk sites between the renin-angiotensin and the kallikrein-kinin systems.
Su JB
J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):319-28. PubMed ID: 23386283
[TBL] [Abstract][Full Text] [Related]
16. C21 preserves endothelial function in the thoracic aorta from DIO mice: role for AT2, Mas and B2 receptors.
González-Blázquez R; Alcalá M; Fernández-Alfonso MS; Steckelings UM; Lorenzo MP; Viana M; Boisvert WA; Unger T; Gil-Ortega M; Somoza B
Clin Sci (Lond); 2021 May; 135(9):1145-1163. PubMed ID: 33899912
[TBL] [Abstract][Full Text] [Related]
17. Contribution of the renin-angiotensin and kallikrein-kinin systems to short-term variability of blood pressure in two-kidney, one-clip hypertensive rats.
Ponchon P; Elghozi JL
Eur J Pharmacol; 1996 Feb; 297(1-2):61-70. PubMed ID: 8851167
[TBL] [Abstract][Full Text] [Related]
18. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade.
Tschöpe C; Schultheiss HP; Walther T
J Cardiovasc Pharmacol; 2002 Apr; 39(4):478-87. PubMed ID: 11904521
[TBL] [Abstract][Full Text] [Related]
19. The intrinsic coagulation-kinin pathway, complement cascades, plasma renin-angiotensin system, and their interrelationships.
Kaplan AP; Ghebrehiwet B; Silverberg M; Sealey JE
Crit Rev Immunol; 1981 Sep; 3(1):75-93. PubMed ID: 7047077
[TBL] [Abstract][Full Text] [Related]
20. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors.
Linz W; Schölkens BA
J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S83-90. PubMed ID: 1282635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
